SC-45 Comparing T-Spot and in-house IGRA for assessing SARS-CoV-2-specific cell-mediated immunity

• Published in: Sexually transmitted infections Vol. 100; no. Suppl 1; pp. A115 - A116
• Main Authors: Benedetti, L, Ferrari, L, Ruggiero, A, Braccialarghe, N, Piermatteo, L, Sarmati, L, Geretti, AM, Iannetta, M
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd 01.06.2024; BMJ Publishing Group LTD
• Subjects: Antiretroviral drugs; HIV; Human immunodeficiency virus; Medical personnel; Peptides; Severe acute respiratory syndrome coronavirus 2; Short Communication; Vaccines

BackgroundDifferent approaches can be used to assess SARS-CoV-2-specific cell-mediated immunity (CMI) as a tool to improve COVID-19 prevention and care in immunocompromised patients, such as people living with HIV. Here we compare our in-house interferon (IFN)-γ release assay (IGRA) with a commercia...